TH and Parkinson disease: The combination gene therapy using both short-acting cDNA-derived TH transgene and long-acting genomic-derived TH transgene provides a more sustained therapeutic duration in experimental PD as compared to single gene therapy using either cDNA-derived or genomic-derived transgene.